<DOC>
	<DOCNO>NCT01071928</DOCNO>
	<brief_summary>The purpose study explore safety activity docetaxel + ASA404 second-line chemotherapy patient advance urothelial carcinoma .</brief_summary>
	<brief_title>Second-Line Docetaxel + ASA404 Advanced Urothelial Carcinoma</brief_title>
	<detailed_description>OUTLINE : This multi-center study . 21 Day Cycle Treatment Regimen : - Docetaxel IV 75 mg/m2 approximately 60 minute Day 1 - ASA404 ( give Docetaxel ) IV 1800 mg/m2 approximately 20 minute Day 1 Treatment continue disease progression intolerable treatment related adverse effect . Karnofsky performance status ≥ 70 % within 7 day prior registration protocol therapy . Life Expectancy : Not specify Hematopoietic : - Hemoglobin ( Hgb ) &gt; 9 g/dL - Platelets &gt; 100 K/mm3 - Absolute neutrophil count ( ANC ) &gt; 1.5 K/mm3 - INR Prothrombin Time ( PT ) &lt; 1.5 x ULN Hepatic : - Bilirubin &lt; 1.5 x ULN - Aspartate aminotransferase ( AST , ALT ) &lt; 2.5 x ULN Renal : - Calculated creatinine clearance &gt; 45 cc/min use Cockcroft-Gault formula Cardiovascular : - No congestive heart failure ( NY Heart Association class III IV ) - No myocardial infarction within 12 month study registration protocol therapy implant cardiac pacemaker - No unstable poorly control angina pectoris , include Prinzmetal variant angina pectoris</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vadimezan</mesh_term>
	<criteria>Histological cytological proof transitional cell carcinoma ( TCC ) bladder , urethra , ureter , renal pelvis ( urothelial carcinoma ) . Histology may mix , still require component TCC . Measurable disease accord RECIST ( version 1.1 ) obtain image within 30 day prior registration protocol therapy . Note : Sites measurable disease within previously irradiate site . Written inform consent HIPAA authorization release personal health information . Age &gt; 18 year time consent . Must receive one prior chemotherapy regimen , must include one follow chemotherapeutic agent : cisplatin , carboplatin , gemcitabine . Note : Prior chemotherapy may administer perioperative ( neoadjuvant/adjuvant ) advanced/metastatic setting . Patients may receive prior treatment paclitaxel . Females childbearing potential male must willing use effective method contraception ( hormonal barrier method birth control ; abstinence ) time consent sign 12 week treatment discontinuation . Females childbearing potential must negative pregnancy test within 7 day prior registration protocol therapy . Females must breastfeed . No prior treatment docetaxel . No symptomatic brain metastasis . Patients neurological symptom must undergo head CT scan brain MRI exclude brain metastasis . NOTE : Patients treat brain metastasis must steroids complete radiation least 14 day prior registration protocol therapy . No prior malignancy allow except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , Gleason &lt; grade 7 prostate cancer , cancer patient diseasefree least 5 year No treatment investigational agent chemotherapeutic agent within 30 day prior registration protocol therapy . No radiotherapy within 14 day prior registration protocol therapy . Patients must recover radiotherapyrelated toxicity . No major surgery within 30 day prior registration protocol therapy ( major surgery define use general anesthesia ) . No minor surgery 14 day prior registration protocol therapy . NOTE : Insertion vascular access device allow . No history medical condition result ≥ CTC grade 2 dyspnea . Patients without long QT syndrome No history labile hypertension poor compliance antihypertensive regimen NOTE : No patient systolic BP &gt; 140 mm Hg and/or diastolic BP &gt; 90 mm Hg medication hypertension . No presence atrial tachyarrhythmia ( e.g. , atrial fibrillation , atrial flutter , multifocal atrial tachycardia , supraventricular tachycardia ) effectively ratecontrolled . No history sustain ventricular tachycardia No history ventricular fibrillation Torsades de Pointes No right bundle branch block leave anterior posterior hemiblock ( bifascicular block ) No bradycardia define heart rate &lt; 50 beat per minute No concomitant use drug risk cause Torsades de Pointes . No concomitant use drug inducer inhibitor UGT1A9 UGT2B7 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Advanced Urothelial Carcinoma</keyword>
</DOC>